Palo Alto Investors LP Rigel Pharmaceuticals Inc Transaction History

Palo Alto Investors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $437,104 - $2.08 Million	-652,395 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $1.16 Million - $1.7 Million	-345,761 Reduced 34.64%	652,395 $2.23 Million
Q4 2020 Feb 16, 2021	SELL	$2.35 - $3.74 $436,949 - $695,400	-185,936 Reduced 15.7%	998,156 $3.49 Million
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $4.2 Million - $9.74 Million	-2,358,459 Reduced 66.58%	1,184,092 $2.84 Million
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $71,680 - $108,864	-44,800 Reduced 1.25%	3,542,551 $7.58 Million
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $649,708 - $1.04 Million	-398,594 Reduced 10.0%	3,587,351 $6.71 Million
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $41,304 - $66,722	19,858 Added 0.5%	3,985,945 $9.17 Million
Q1 2018 May 15, 2018	BUY	$3.54 - $4.54 $107,980 - $138,483	30,503 Added 0.78%	3,966,087 $14 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $260,208 - $346,408	80,560 Added 2.09%	3,935,584 $15.3 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $8.4 Million - $9.91 Million	3,855,024	3,855,024 $9.79 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.2B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

Stay updated on Palo Alto Investors LP with notifications on news.